{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T04:52:50Z","timestamp":1771995170895,"version":"3.50.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2008,3,1]],"date-time":"2008-03-01T00:00:00Z","timestamp":1204329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,3,1]],"date-time":"2008-03-01T00:00:00Z","timestamp":1204329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2008,3]]},"DOI":"10.1016\/j.metabol.2007.10.014","type":"journal-article","created":{"date-parts":[[2008,2,8]],"date-time":"2008-02-08T09:31:04Z","timestamp":1202463064000},"page":"380-386","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Differential effect of atorvastatin and fenofibrate on plasma oxidized low-density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus"],"prefix":"10.1016","volume":"57","author":[{"given":"Jean-Charles","family":"Hogue","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beno\u00eet","family":"Lamarche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9 J.","family":"Tremblay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Bergeron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claude","family":"Gagn\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Couture","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2007.10.014_bib1","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/nature01323","article-title":"Inflammation in atherosclerosis","volume":"420","author":"Libby","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.metabol.2007.10.014_bib2","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1161\/hc0502.104540","article-title":"Fundamentals of endothelial function for the clinical cardiologist","volume":"105","author":"Verma","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2007.10.014_bib3","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s11883-006-0040-x","article-title":"C-reactive protein and cardiovascular disease: weighing the evidence","volume":"8","author":"Lowe","year":"2006","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.metabol.2007.10.014_bib4","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1161\/01.CIR.103.9.1194","article-title":"C-reactive protein\u2013mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis","volume":"103","author":"Zwaka","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2007.10.014_bib5","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.cca.2005.12.030","article-title":"Circulating markers of endothelial function in cardiovascular disease","volume":"368","author":"Constans","year":"2006","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.metabol.2007.10.014_bib6","doi-asserted-by":"crossref","first-page":"20963","DOI":"10.1074\/jbc.272.34.20963","article-title":"Low density lipoprotein oxidation and its pathobiological significance","volume":"272","author":"Steinberg","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.metabol.2007.10.014_bib7","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0008-6363(00)00118-8","article-title":"Oxidative stress and cardiovascular complications in diabetes: isoprostanes as new markers on an old paradigm","volume":"47","author":"Mezzetti","year":"2000","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.metabol.2007.10.014_bib8","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1161\/res.90.3.251","article-title":"Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly","volume":"90","author":"Galis","year":"2002","journal-title":"Circ Res"},{"key":"10.1016\/j.metabol.2007.10.014_bib9","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1161\/01.ATV.0000054195.35121.5E","article-title":"Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease","volume":"23","author":"Marx","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.metabol.2007.10.014_bib10","first-page":"RA5","article-title":"Lysophosphatidylcholine and secretory phospholipase A2 in vascular disease: mediators of endothelial dysfunction and atherosclerosis","volume":"12","author":"Kougias","year":"2006","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.metabol.2007.10.014_bib11","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1172\/JCI10762","article-title":"Insulin resistance and cardiovascular disease","volume":"106","author":"Ginsberg","year":"2000","journal-title":"J Clin Invest"},{"key":"10.1016\/j.metabol.2007.10.014_bib12","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1161\/01.CIR.98.19.2088","article-title":"Mechanism of action of fibrates on lipid and lipoprotein metabolism","volume":"98","author":"Staels","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2007.10.014_bib13","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S0002-9149(97)00965-X","article-title":"Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)","volume":"81","author":"Jones","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.metabol.2007.10.014_bib14","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/00041433-199912000-00010","article-title":"Low-density lipoprotein\u2013independent effects of statins","volume":"10","author":"Davignon","year":"1999","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.metabol.2007.10.014_bib15","doi-asserted-by":"crossref","first-page":"614","DOI":"10.2337\/diacare.20.4.614","article-title":"Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)","volume":"20","author":"Pyorala","year":"1997","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2007.10.014_bib16","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2007.10.014_bib17","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1016\/j.metabol.2007.10.014_bib18","first-page":"S5","article-title":"Report of the Expert Committee on the Diagnosis and classification of diabetes mellitus","volume":"27","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2007.10.014_bib19","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1161\/01.CIR.103.15.1933","article-title":"Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels","volume":"103","author":"Jialal","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2007.10.014_bib20","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1365-2362.1993.tb00776.x","article-title":"Decreased in vitro oxidizability of low-density lipoprotein in hypercholesterolaemic patients treated with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors","volume":"23","author":"Kleinveld","year":"1993","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.metabol.2007.10.014_bib21","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/S0002-9149(99)80552-9","article-title":"Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability","volume":"75","author":"Bredie","year":"1995","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.metabol.2007.10.014_bib22","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0009-8981(01)00549-6","article-title":"Effect of atorvastatin on LDL oxidation and antioxidants in normocholesterolemic type 2 diabetic patients","volume":"311","author":"Oranje","year":"2001","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.metabol.2007.10.014_bib23","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/0006-2952(96)00245-6","article-title":"Lovastatin reduces expression of the combined adhesion and scavenger receptor CD36 in human monocytic cells","volume":"52","author":"Pietsch","year":"1996","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.metabol.2007.10.014_bib24","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S0140-6736(05)76154-7","article-title":"Effect of statins on C-reactive protein in patients with coronary artery disease","volume":"353","author":"Strandberg","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2007.10.014_bib25","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1161\/01.ATV.18.11.1671","article-title":"HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages","volume":"18","author":"Bellosta","year":"1998","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.metabol.2007.10.014_bib26","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1527-3466.2006.00033.x","article-title":"C-reactive protein (CRP)-lowering agents","volume":"24","author":"Prasad","year":"2006","journal-title":"Cardiovasc Drug Rev"},{"key":"10.1016\/j.metabol.2007.10.014_bib27","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1161\/01.RES.0000127122.22685.0A","article-title":"Peroxisome proliferators\u2013activated receptors and atherogenesis: regulators of gene expression in vascular cells","volume":"94","author":"Marx","year":"2004","journal-title":"Circ Res"},{"key":"10.1016\/j.metabol.2007.10.014_bib28","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1161\/hq0402.105901","article-title":"Elevated soluble cellular adhesion molecules in subjects with low HDL-cholesterol","volume":"22","author":"Calabresi","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.metabol.2007.10.014_bib29","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1475-2840-2-17","article-title":"Differential effects of fenofibrate versus atorvastatin on the concentrations of E-selectin and vascular cellular adhesion molecule\u20131 in patients with type 2 diabetes mellitus and mixed hyperlipoproteinemia: a randomized cross-over trial","volume":"2","author":"Empen","year":"2003","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.metabol.2007.10.014_bib30","doi-asserted-by":"crossref","first-page":"241","DOI":"10.5414\/CPP41241","article-title":"Effects of fenofibrate and simvastatin on plasma sICAM-1 and MCP-1 concentrations in patients with hyperlipoproteinemia","volume":"41","author":"Kowalski","year":"2003","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.metabol.2007.10.014_bib31","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1080\/10715760410001665244","article-title":"Dual role of oxidized LDL on the NF-kappaB signaling pathway","volume":"38","author":"Robbesyn","year":"2004","journal-title":"Free Radic Res"},{"key":"10.1016\/j.metabol.2007.10.014_bib32","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJM199901143400207","article-title":"Atherosclerosis\u2014an inflammatory disease","volume":"340","author":"Ross","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2007.10.014_bib33","doi-asserted-by":"crossref","first-page":"4489","DOI":"10.1210\/jc.2006-0299","article-title":"Direct demonstration of an anti-inflammatory effect of simvastatin in subjects with the metabolic syndrome","volume":"91","author":"Devaraj","year":"2006","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049507003745?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049507003745?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T03:32:13Z","timestamp":1758425533000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049507003745"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,3]]}},"alternative-id":["S0026049507003745"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2007.10.014","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2008,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Differential effect of atorvastatin and fenofibrate on plasma oxidized low-density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2007.10.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}